Biomarkers of oxidative/nitrosative stress: An approach to disease prevention

Acta Medica Okayama

Volumn 61, Issue 4, 2007, Pages 181-189

  Ogino, Keiki ^a   Wang, Da Hong ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Biomarker; Disease prevention; Molecular epidemiology; Oxidative nitrosative stress

Indexed keywords

BIOLOGICAL MARKER; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

HUMAN; METABOLISM; METHODOLOGY; OXIDATIVE STRESS; PHYSIOLOGY; PRIMARY PREVENTION; REVIEW;

BIOLOGICAL MARKERS; HUMANS; OXIDATIVE STRESS; PRIMARY PREVENTION; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

EID: 34848827135     PISSN: 0386300X     EISSN: 0386300X     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Halliwell B and Gutteridge JMC: Oxidative stress; in Free radicals in biology and medicine, Halliwell B and Gutteridge JMC eds, 3 rd Ed, Oxford University Press, Oxford University Press, New York (1999) pp 246-350.
2. Sies H: Oxidative stress: from basic research to clinical application. Am J Med (1991) 91: 31S-38S.
3. Cutler RG, Plummer J, Chowdhury K and Heward C: Oxidative stress profiling: part II. Theory, technology, and practice. Ann N Y Acad Sci (2005) 1055: 136-158.
4. Committee on Biological Markers of the National Research Council: Biological markers in environmental health research. Environ Health Perspect (1987) 74: 3-9.
5. Bonassi S and Au WW: Biomarkers in molecular epidemiology studies for health risk prediction. Mutat Res (2002) 511: 73-86.
6. Griffiths HR, Moller L, Bartosz G, Bast A, Bertoni-Freddari C, Collins A, Cooke M, Coolen S, Haenen G, Hoberg AM, Loft S, Lunec J, Olinski R, Parry J, Pompella A, Poulsen H, Verhagen H and Astley SB: Biomarkers. Mol Aspects Med (2002) 23: 101-208.
7. Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R and Milzani A: Protein carbonylation, cellular dysfunction, and disease progression. J Cell Mol Med (2006) 10: 389-406.
8. Berlett BS and Stadman ER: Protein oxidation in aging, disease, and oxidative stress. J Biol Chem (1997) 272: 20313-20316.
9. Levine RL: Carbonyl modified proteins in cellular regulation, aging, and disease. Free Radic Biol Med (2002) 32: 790-796.
10. Gieseg S, Duggan S and Gebicki JM: Peroxidation of proteins before lipids in U937 cells exposed to peroxyl radicals. Biochem J (2000) 350: 215-218.
11. Stadtman ER and Levine RL: Protein oxidation. Ann NY Acad Sci (2000) 899: 191-208.
12. Du J and Gebicki JM: Proteins are major initial cell targets of hydroxyl free radicals (2004) 36: 2334-2343.
13. Shacter E: Quantification and significance of protein oxidation in biological samples. Drug Metab Rev (2000) 32: 307-326.
14. Beal MF: Oxidatively modified proteins in aging and disease. Free Radic Biol Med (2002) 32: 797-803.
15. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA and Himmelfarb J: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int (2004) 65: 1009-1016.
16. Renke J, Popadiuk S, Korzon M, Bugajczyk B and Wozniak M: Protein carbonyl groups' content as a useful clinical marker of antioxidant barrier impairment in plasma of children with juvenile chronic arthritis. Free Radic Biol Med (2000) 29: 101-104.
17. Pantke U, Volk T, Schmutzler M, Kox WJ, Sitte N and Grune T: Oxidized proteins as a marker of oxidative stress during coronary heart surgery. Free Radic Biol Med (1999) 27: 1080-1086.
18. Stadtman ER and Levine RL: Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids (2003) 25: 207-218.
19. Dalle-Donne I, Rossi R, Giustarini D, Milzani A and Colombo R: Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta (2003) 329: 23-38.
20. Choi J, Malakowsky CA, Talent JM, Conrad CC and Gracy RW: Identification of oxidized plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun (2002) 293: 1566-1570.
21. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Merchant M, Markesbery WR and Butterfield DA: Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: Anapproach to understand pathological and biochemical alterations in AD. Neurobiol Aging (2006) 27: 1564-1576.
22. Halliwell B: What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? FEBS Lett (1997) 411: 157-160.
23. Bo S, Gambino R, Guidi S, Silli B, Gentile L, Cassader M and Pagano GF: Plasma nitrotyrosine levels, antioxidant vitamins and hyperglycemia. Diabetic Med (2005) 22: 1185-1189.
24. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, Gokce N, Keaney JF Jr., Penn MS, Sprecher DL, Vita JA and Hazen SL: Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA (2003) 289: 1675-1680.
25. Fenster CP, Darley-Usmar VM, Landar AL, Gower BA, Weinsier RL, Hunter GR and Patel RP: Weight Loss and Race Modulate Nitric Oxide Metabolism in Overweight Women. Free Radic Biol Med (2004) 37: 695-702.
26. Duncan MW: A review of approaches to the analysis of 3-nitrotyrosine. Amino Acids (2003) 25: 351-361.
27. Tsikas D and Caidahl K: Recent methodological advances in the mass spectrometric analysis of free and protein-associated 3-nitrotyrosine in human plasma. J Chromatogr B (2005) 814: 1-9.
28. Aulak KS, Miyagi M, Yan L, West KA, Massillon D, Crabb JW and Stuehr DJ: Proteomic method identifies proteins nitrated in vivo during inflammatory challenge. Proc Natl Acad Sci USA (2001) 98: 12056-12061.
29. Turko IV, Li L, Aulak KS, Stuehr DJ, Chang JY and Murad F: Protein tyrosine nitration in the mitochondria from diabetic mouse heart. J Biol Chem (2003) 278: 33972-33977.
30. Elfering SL, Haynes VL, Traaseth NJ, Ettl A and Giulivi C: Aspects, mechanism, and biological relevance of mitochondrial protein nitration sustained by mitochondrial nitric oxide synthase. Am J Physiol Heart Circ Physiol (2004) 286: H22-H29.
31. Kanski J, Behring A, Pelling J and Schoneich C: Proteomic identification of 3-nitrotyrosine-containing rat cardiac proteins: effects of biological aging. Am J Physiol Heart Circ Physiol (2005) 288: H371-H381.
32. Kanski J, Hong SJ and Schoneich C: Proteomic analysis of protein nitration in aging skeletal muscle and identification of nitrotyrosine- containing sequences in vivo by nanoelectrospray ionization tandem mass spectrometry. J Biol Chem (2005) 280: 24261-24266.
33. Granger CB, Van Eyk JE, Mockrin SC and Anderson NL: National Heart, Lung, And Blood Institute Clinical Proteomics Working Group report. Circulation (2004) 109: 1697-1703.
34. Kono Y, Nakamura K, Kimura H, Nishii N, Watanabe A, Banba K, Miura A, Nagase S, Sakuragi S, Kusano KF, Matsubara H and Ohe T: Elevated Levels of Oxidative DNA Damage in Serum and Myocardium of Patients With Heart Failure. Circ J (2006) 70: 1001 -1005.
35. Sato S, Mizuno Y and Hattori N: Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology (2005) 64: 1081-1083.
36. Halliwell B and Whiteman M: Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol (2004) 142: 231-255.
37. Collins AR, Cadet J, Moller L, Poulsen HE and Vina J: Are we sure we know how to measure 8-oxo-7,8-dihydroguanine in DNA from human cells? Arch Biochem Biophys (2004) 423: 57-65.
38. Hu CW, Wu MT, Chao MR, Pan CH, Wang CJ, Swenberg JA and Wu KY: Comparison of analyses of urinary 8-hydroxy-2-deoxyguanosine by isotope-dilution liquid chromatography with electrospray tandem mass spectrometry and by enzyme-linked immunosorbent assay. Rapid Commun Mass Spectrom (2004) 18: 505-510.
39. Kimura S, Yamauchi H, Hibino Y, Iwamoto M, Sera K and Ogino K: Evaluation of urinary 8-hydroxydeoxyguanine in healthy Japanese people. Basic Clin Pharmacol Toxicol (2006) 98: 496-502.
40. Moller P and Loft S: Dietary antioxidants and beneficial effect on oxidatively damaged DNA. Free Radic Biol Med (2006) 41: 388-415.
41. Gackowski D, Rozalski R, Roszkowski K, Jawien A, Foksinski M and Olinski R: 8-Oxo-7,8-dihydroguanine and 8-oxo-7,8-dihydro-2′-deoxyguanosine levels in human urine do not depend on diet. Free Radic Res (2001) 35: 825-832.
42. Park EM, Shigenaga MK, Degan P, Korn TS, Kitzler JW, Wehr CM, Kolachana P and Ames BN: Assay of excised oxidative DNA lesions: isolation of 8-oxoguanine and its nucleoside derivatives from biological fluids with a monoclonal antibody column. Proc Natl Acad Sci USA (1992) 89: 3375-3379.
43. Ohshima H, Sawa T and Akaike T: 8-nitroguanine, a product of nitrative DNA damage caused by reactive nitrogen species: formation, occurrence, and implications in inflammation and carcinogenesis. Antioxid Redox Signal (2006) 8: 1033-1045.
44. Akaike T, Okamoto S, Sawa T, Yoshitake J, Tamura F, Ichimori K, Miyazaki K, Sasamoto K and Maeda H: 8-nitroguanosine formation in viral pneumonia and its implication for pathogenesis. Proc Natl Acad Sci USA (2003) 100: 685-690.
45. Ma N, Adachi Y, Hiraku Y, Horiki N, Horiike S, Imoto I, Pinlaor S, Murata M, Semba R and Kawanishi S: Accumulation of 8-nitroguanine in human gastric epithelium induced by Helicobacter pylori infection, Biochem Biophys Res Commun (2004) 319: 506-510.
46. Horiike S, Kawanishi S, Kaito M, Ma N, Tanaka H, Fujita N, Iwasa M, Kobayashi Y, Hiraku Y, Oikawa S, Murata M, Wang J, Semba R, Watanabe S and Adachi Y: Accumulation of 8-nitroguanine in the liver of patients with chronic hepatitis C. J Hepatol (2005) 43: 403-410.
47. Pinlaor S, Ma N, Hiraku Y, Yongvanit P, Semba R, Oikawa S, Murata M, Sripa B, Sithithaworn P and Kawanishi S: Repeated infection with Opisthorchis viverrini induces accumulation of 8-nitroguanine and 8-oxo-7,8-dihydro-2′- deoxyguanine in the bile duct of hamsters via inducible nitric oxide synthase. Carcinogenesis (2004) 25: 1535-1542.
48. Ma N, Tagawa T, Hiraku Y, Murata M, Ding X and Kawanishi S: 8-Nitroguanine formation in oral leukoplakia, a premalignant lesion. Nitric Oxide (2006) 14: 137-143.
49. Sawa T, Tatemichi M, Akaike T, Barbin A and Ohshima H: Analysis of urinary 8-nitroguanine, a marker of nitrative nucleic acid damage, by high-performance liquid chromatography-electrochemical detection coupled with immunoaffinity purification: association with cigarette smoking. Free Radic Biol Med (2006) 40: 711-720.
50. Yeo HC, Helbock HJ, Chyu DW and Ames BN: Assay of malondialdehyde in biological fluids by gas chromatography-mass spectrometry. Anal Biochem (1994) 220: 391-396.
51. Halliwell B: Lipid peroxidation, antioxidants and cardiovascular disease: how should we move forward? Cardiovasc Res (2000) 47: 410-418.
52. Walter MF, Jacob RF, Jeffers B, Ghadanfar MM, Preston GM, Buch J and Mason RP: Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease. J Am Coll Cardiol (2004) 44: 1996-2002.
53. Milne GL, Musiek ES and Morrow JD: F2-isoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers (2005) Suppl 1: S10-23.
54. Gopaul NK, Halliwell B and Anggard EE: Measurement of plasma F2- isoprostanes as an index of lipid peroxidation does not appear to be confounded by diet. Free Radic Res (2000) 33: 115-127.
55. Montuschi P, Barnes PJ and Roberts LJ: Isoprostanes: markers and mediators of oxidative stress. FASEB J (2004) 18: 1791-1800.
56. Wu JT: Advanced glycosylation end products: a new disease marker for diabetes and aging. J Clin Lab Anal (1993) 7: 252-255.
57. Miyata T, Maeda K, Kurokawa K and van Ypersele de Strihou C: Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant (1997) 12: 255-258.
58. Singh R, Barden A, Mori T and Beilin L: Advanced glycation end-products: a review. Diabetologia (2001) 44: 129-146.
59. Degenhardt TP, Grass L, Reddy S, Thorpe SR, Diamandis EP and Baynes JW: Technical note. The serum concentration of the advanced glycation end-product N epsilon-(carboxymethyl)lysine is increased in uremia. Kidney Int (1997) 52: 1064-1067.
60. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K, van Ypersele de Strihou C and Maeda K: Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol (1996) 7: 1198 -1206.
61. Kanauchi M, Nishioka H and Dohi K: Serum levels of advanced glycosylation end products in diabetic nephropathy. Nephron (2001) 89: 228-230.
62. Koga K, Yamagishi S, Okamoto T, Inagaki Y, Amano S, Takeuchi M and Makita Z: Serum levels of glucose-derived advanced glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal dysfunction. Int J Clin Pharmacol Res (2002) 22: 13-17.
63. Kilhovd BK, Juutilainen A, Lehto S, Rönnemaa T, Torjesen PA, Birkeland KI, Berg TJ, Hanssen KF and Laakso M: High Serum Levels of Advanced Glycation End Products Predict Increased Coronary Heart Disease Mortality in Nondiabetic Women but not in Nondiabetic Men. Arteriosclerosis, Thrombosis, and Vascular Biology (2005) 25: 815-820.
64. Mitushashi T, Vlassara H, Founds HW and Li YM: Standardizing the immunological measurement of advanced glycation endproducts using normal human serum. J Immunol Methods (1997) 207: 79-88.
65. Koschinski T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K and Vlassara H: Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA (1997) 94: 6474-6479.
66. Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R and Cerami A: Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA (1997) 94: 13915-13920.
67. Albertini RJ: Biomarker responses in human populations: towards a worldwide map. Mutat Res (1999) 428: 217-226.
68. Merlo DF, Sormani MP and Bruzzi P: Molecular epidemiology: New rules for new tools? Mutat Res (2006) 600: 3-11.
69. Bonassi S, Neri M and Puntoni R: Validation of biomarkers as early predictors of disease. Mutat Res (2001) 480-481: 349-358.
70. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA and Thacker SB: Metaanalysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA (2000) 283: 2008-2012.
71. Halliwell B: Establishing the significance and optimal intake of dietary antioxidants: the biomarker concept. Nutr Rev (1999) 57: 104-113.
72. Halliwell B, Rafter J and Jenner A: Health promotion by flavonoids, tocopherols, tocotrienols, and other phenols: direct or indirect effects? Antioxidant or not? Am J Clin Nutr (2005) 81(Suppl 1): 268S-276S.
73. Lee CYJ, Isaac HB, Wang H, Huang SH, Long LH, Jenner AM, Kelly RP and Halliwell B: Cautions in the use of biomarkers of oxidative damage; the vascular and antioxidant effects of dark soy sauce in humans. Biochem Biophys Res Commun (2006) 344: 906 -911.
74. Carty JL, Bevan R, Waller H, Mistry N, Cooke M, Lunec J and Griffiths HR: The Effects of Vitamin C Supplementation on Protein Oxidation in Healthy Volunteers. Biochem Biophys Res Commun (2000) 273: 729-735.
75. Mullan BA, Young IS, Fee H and McCance DR: Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes. Hypertension (2002) 40: 804-809.
76. GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico): Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. The Lancet (1999) 354: 447-455.
77. Yusuf S, Dagenais G, Pogue J, Bosch J and Sleight P: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 342: 154-160.
78. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL Jr, Valanis B, Williams JH Jr, Barnhart S, Cherniack MG, Brodkin CA and Hammar S: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst (1996) 88: 1550-1559.